Maher, T. M., Brown, K. K., Kreuter, M., Devaraj, A., Walsh, S. L. F., Lancaster, L. H., . . . Flaherty, K. R. (2022). Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. The European respiratory journal, 59(2), . https://doi.org/10.1183/13993003.04587-2020
Chicago-Zitierstil (17. Ausg.)Maher, Toby M., et al. "Effects of Nintedanib by Inclusion Criteria for Progression of Interstitial Lung Disease." The European Respiratory Journal 59, no. 2 (2022). https://doi.org/10.1183/13993003.04587-2020.
MLA-Zitierstil (9. Ausg.)Maher, Toby M., et al. "Effects of Nintedanib by Inclusion Criteria for Progression of Interstitial Lung Disease." The European Respiratory Journal, vol. 59, no. 2, 2022, https://doi.org/10.1183/13993003.04587-2020.